OPINION AND ORDER
I. INTRODUCTION
Plaintiffs bring this securities fraud action under Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.
Vivendi is collaterally estopped from denying any of the elements of plaintiffs’ Section 10(b) claim save for reliance; plaintiffs are entitled to the fraud on the market presumption of reliance; and neither truth on the market nor allegations of no price impact are available as defenses to that presumption.
In short, the only issue in this case is whether Vivendi can rebut the fraud on the market presumption of reliance. Moreover, Vivendi must attempt this rebuttal without arguing that the market for Vivendi ADS’s was inefficient, that there was no price impact, that the truth about Vivendi’s misstatements was known to the market, or that the plaintiffs were in possession of corrective non-public information. A bench trial on this narrow issue was held from February 18, 2013 to February 19, 2013. The following findings of fact and conclusions of law are made under Rule 52(a) of the Federal Rules of Civil Procedure (“FRCP”). In reaching these findings and conclusions, I heard the evidence, observed the demeanor of the witnesses, and considered the arguments and submissions of counsel. For the following reasons, judgment shall be entered in favor of Vivendi.
II. FINDINGS OF FACT
1. Plaintiffs
The plaintiffs in this case are a number of companies that, during the Relevant Period, were subsidiaries of Gabelli Asset Management, Inc. (“GBL,” and collectively with its subsidiaries, the “Gabelli Family”).
During the same period, Gabelli Funds, LLC, another subsidiary of GBL, managed plaintiffs GAMCO Global Series Funds, Inc., Gabelli Capital Asset Fund, The Gabelli Value Fund, Inc., The Gabelli Asset Fund, The Gabelli Global Multimedia Trust, Inc., and The Gabelli Equity Trust, Inc. (collectively, the “Mutual Fund Plaintiffs,” and collectively with GAMCO, the “Plaintiffs”).
Specifically, during the Relevant Period, investment analysts employed by Gabelli & Co. performed research for the benefit of, among others, portfolio managers at GAM-CO and the Mutual Fund Plaintiffs, and reported the results of this research, — as well as recommendations as to whether to buy, sell, or hold securities — at daily morning meetings held by GBL.
2. Defendant
Defendant Vivendi is a French multimedia company that listed ADS’s on the NYSE during the Relevant Period. Beginning in the late 1990s, it engaged in a series of mergers and acquisitions, including a three-way merger between Vivendi, The Seagram Company Ltd., and Canal Plus, S.A. that was announced on October 30, 2000. As a result of this activity, Vivendi took on significant debt, and eventually faced a liquidity crisis. The material misstatements and omissions during the Relevant Period all relate to Vivendi’s alleged attempts to cover up this liquidity crisis.
In the class action, plaintiffs’ expert witness, Dr. Blaine Nye, identified January 7, 2002, May 3, June 21, June 24, July 2, July 3, July 10, July 15, and August 14, 2002 as dates on which corrective disclosures revealed Vivendi’s true liquidity condition and alleged fraud.
B. The Witnesses
Five witnesses testified at the trial: Andrew Rittenberry, Douglas Jamieson, Bruce Alpert, Anthony Hartswell Woodson III,
Like Rittenberry, Jamieson graduated from Columbia Business School before starting his career at the Gabelli Family in 1981.
After earning a Master’s degree in Business Administration from Rensselaer Polytechnic Institute in 1974, Alpert worked as an auditor for PriceWaterhouse for eight years, before leaving to serve as Vice-President and Treasurer of Smith Barney’s mutual funds for two years.
Woodson worked for a company in the Gabelli Family — likely GBL — from November of 1993 to February 28, 2006.
Mario Gabelli founded Gabelli & Company on January 1, 1977, and he has worked for the Gabelli Family ever since.
A few words on Gabelli’s demeanor and credibility are warranted. Gabelli appeared ill at ease with answering direct questions candidly, as if he took his oath subject to the reservation that he be permitted to define “the truth.” Consistent with this understanding, Gabelli interpreted simple questions as invitations to philosophize, prevaricate, and palaver.
Gabelli’s attitude is fairly encapsulated by an answer he gave when confronted with his deposition testimony during the trial:
Q [Reading a passage from Gabelli’s deposition transcript] Was that answer true at the time you gave it?
A. There were many questions prior to that, and I tend to talk a lot and explain a lot. Obviously, I’m not going to say this is not true, but I don’t know the context in which it’s true or not true.38
During summations, Plaintiffs’ counsel stated: “I would ask that you accept [Gabelli] as a person who wants to be precise and that he is trying to be precise in a very important case.”
C. Plaintiffs’ Decision to Buy Vivendi ADS’s
1. Plaintiffs’ Investment Philosophy
Plaintiffs’ investment philosophy is to “identify companies with dominant industry positions that are selling at substantial discounts to their intrinsic Private Market Values [ (“PMV”]) [,]”
GBL invests in a company when its PMV is substantially higher than its market capitalization, and there is a “catalyst,” i.e., “some dynamic that is going to ... cause the market price to rise to the level of’ PMV.
During the Relevant Period, Rittenberry — the only analyst at GBL following Vivendi — calculated the PMV of Vivendi using the proprietary techniques that he learned at Gabelli & Co.
Based on his calculation of Vivendi’s PMV, and the spread between that PMV and the market price of Vivendi securities, Rittenberry consistently gave a “buy” or “hold” recommendation on Vivendi securities during the Relevant Period.
I find that Rittenberry’s conclusion that Vivendi’s liquidity crisis was a short-term concern that made it a more attractive investment, by reducing the public market price of Vivendi securities without reducing its PMV, was shared by the Gabelli Family, including Mario Gabelli. On July 1, 2002, Mario Gabelli commented that Vivendi had “a wonderful array of assets,” and that “Vivendi is a good business!!;]” on June 25, 2007, Gabelli testified that his “view of [Vivendi’s] assets has not changed;”
Plaintiffs’ Corrective Disclosure Period purchases of Vivendi ADS’s reinforce my finding that Vivendi’s liquidity crisis was irrelevant to Plaintiffs’ decision to purchase Vivendi securities during the Relevant Period. One example is particularly telling. On July 1, 2002, Moody’s downgraded Vivendi to junk status; the next day, Standard & Poor’s downgraded Vivendi to one notch above junk status.
In sum, I find that, throughout the Relevant Period: (1) Plaintiffs were value-based investors who utilized a propriety metric known as PMV to evaluate the intrinsic value of Vivendi securities; (2) the calculation of PMV relied upon by Plaintiffs to evaluate Vivendi was significantly higher than Vivendi’s market price; (3) the market price of Vivendi securities factored into Plaintiffs’ investment decision only as a comparator with PMV; and (4) the liquidity crisis at Vivendi was irrelevant to Plaintiffs’ investment decisions, except to the extent that each corrective disclosure made Vivendi a more attractive investment, by increasing the spread between Vivendi’s PMV and its market price.
III. APPLICABLE LAW
A. The Fraud on the Market Presumption Under Section 10(b)
“[Rjeliance upon [a] misrepresentation or omission” is an element of a private securities fraud claim brought under Section 10(b) and Securities and Exchange Commission Rule 10b-5.
In Basic v. Levinson the Supreme Court held that an investor who bought or sold securities in an efficient market may avail herself of the presumption that she “relied on the integrity of the price set by the market....”
The fraud on the market presumption announced in Basic allowed plaintiffs to proceed with securities fraud claims without having to show that they were personally aware of, and relied on, a eompany’s misrepresentations. Through this rule, the Supreme Court sought to alleviate the difficult evidentiary issues and problems with class certification that commonly arise in securities fraud actions.
The Second Circuit has consistently stated that “[t]he ... fraud-on-the-market theory involves two rebuttable presumptions that permit a finding of ... reliance ...: ‘that (1) misrepresentations by an issuer affect the price of securities traded in the open market, and (2) investors rely on the market price of securities as an accurate measure of their intrinsic value.’ ”
In order to invoke the fraud on the market presumption, “plaintiffs must demonstrate that the alleged misrepresentations were publicly known[,] ... that the stock traded in an efficient market, and that the relevant transaction took place between the time the misrepresentations were made and the time the truth was revealed.”
Basic states that: “[a]ny showing that severs the link between the alleged misrepresentation and either the price received (or paid) by the plaintiff, or [her] decision to trade at a fair market price, will be sufficient to rebut the presumption of reliance.”
The first example — sometimes termed “truth on the market” — could be classified as a mode of negating fraud entirely, rather than rebutting the fraud on the market theory.
True rebuttals of the presumption — ie., arguments that the investors in question did not in fact “rely on the market price of securities as an accurate measure of their intrinsic value”
This case turns entirely on whether Vivendi has successfully rebutted Plaintiffs’ reliance on the misrepresentations and omissions that were incorporated into the market price of Vivendi ADS’s. In addressing how individual reliance may be rebutted, the Basic court explained:
Petitioners also could rebut the presumption of reliance as to plaintiffs who would have divested themselves of their Basic shares without relying on the integrity of the market. For example, a plaintiff who believed that Basic’s statements [falsely disclaiming the possibility of a merger] were false and that Basic was indeed engaged in merger discussions, and who consequently believed that Basic stock was artificially under-priced, but sold his shares nevertheless because of other unrelated concerns, e.g., potential antitrust problems, or political pressures to divest from shares of certain businesses, could not be said to have relied on the integrity of a price he knew had been manipulated.86
This quote illustrates that the fraud on the market presumption is rebuttable when the plaintiff traded “without relying on the integrity of the market.”
Even before Basic, one court held that “given the force of the [fraud on the market] presumption (carrying a burden of proving a purchase would have been made even if the truth were known)[,]” attempts to rebut the presumption “would likely be futile in the vast number of cases.”
Based on the findings of fact set forth above, I conclude that this is just such an extraordinary case. As the Supreme Court recently explained, the fraud on the market presumption of reliance arises because, in an efficient market:
[I]t is reasonable to presume that most investors — knowing that they have little hope of outperforming the market in the long run based solely on their analysis of publicly available information — will rely on the security’s market price as an unbiased assessment of the security’s value in light of all public information. Thus, courts may presume that investors trading in efficient markets indirectly rely on public, material misrepresentations through their reliance on the integrity of the price set by the market.92
The Supreme Court has also stated that: “[r]eliance ... upon the defendant’s deceptive acts is an essential element of the § 10(b) private cause of action ... because proof of reliance ensures that there is a proper connection between a defendant’s misrepresentation and a plaintiffs injury.”
Quite the contrary: PMV, the metric that Plaintiffs used to determine the intrinsic value of Vivendi ADS’s, is completely independent of liquidity concerns and market price. There is no indication in the record that Plaintiffs would have
In other words, but for the alleged misrepresentations and omissions, Plaintiffs would have been more likely to invest in Vivendi. Accordingly, it is more likely than not that during the Relevant Period, Plaintiffs did not “rely on the market price of [Vivendi] securities as an accurate measure of their intrinsic value.’ ”
This holding is sharply limited to its unusual facts, and should not be taken to suggest that sophisticated institutional investors or value-based investors are not entitled to the fraud on the market presumption in general. As courts in this Circuit have routinely held, the use of sophisticated investment models does not foreclose a finding of material reliance on market price.
Because few securities cases proceed to trial — and fewer still are bench trials— there are few precedents addressing the narrow issue presented here. The closest case on point appears to be Black v. Finantra Capital, Inc.
The Second Circuit reversed, holding that:
The jury was free to weigh all the testimony, and either to discredit it or to accept a different interpretation of Black’s testimony that the current market price was “not really relevant when you can’t sell the stock for six months or three months,” (Tr. at 104.), or to credit Black’s testimony that he took market price into account, because, not surprisingly, the current market price was what determined whether he was “making a good deal.” (Tr. at 50.) The fact thatBlack also took other considerations, such as Finantra’s future prospects, its business plan, and his trust in the people soliciting his investment, into account in making his investment decision does not foreclose a finding of material reliance upon market price. 101
The statement that the jury could have properly found reliance on the basis that the current market price determined whether Black was “making a good deal” could be taken to suggest that, once it attaches, the fraud on the market presumption is irrebuttable as against any plaintiff who buys a security at market price. This reading is overly broad: had the Second Circuit intended to announce such a sweeping principle, it would have done so. Basic plainly allows for the presumption to be rebutted when the plaintiff would have transacted in the security regardless of market price,
Unlike Herbert Black, the Plaintiffs did not materially rely on market price in making their investment decision. Instead, as detailed above, had Vivendi’s fraud been known to the market, the Plaintiffs would have been all the more eager to invest — which indeed they did, throughout the Corrective Disclosure Period. Adopting Vivendi’s useful formulation of the transaction causation test, the market price of Vivendi ADS’s was not the “motivating driving force” behind Plaintiffs’ investment decision.
During closing, counsel for Plaintiffs repeatedly stated that Plaintiffs had “relied on price.”
Plaintiffs support their “same price” argument with citations to two District Court cases from this Circuit.
Plaintiffs have also argued that the fact that Plaintiffs based their evaluation of Vivendi ADS’s on PMV “ ‘should not defeat the fraud-on-the-market presumption absent convincing proof that price played no part whatsoever in their decision making’ process.”
During closing argument, I raised my concern that Plaintiffs were describing an irrebuttable presumption, and asked Plaintiffs’ counsel how, in his view, the fraud on the market presumption could be rebutted.
Contrary to Plaintiffs’ view, the examples given in Basic were not meant to be exhaustive. Basic holds that “[a]ny showing that severs the link between the alleged misrepresentation and ... the plaintiff[’s] ... decision to trade at a fair market price, will be sufficient to rebut the presumption of reliance.”
V. CONCLUSION
Based on the findings of fact and conclusions of law stated above, I hold that Vivendi has rebutted the fraud on the market presumption of reliance. The Clerk of the Court is directed to enter judgment in Vivendi’s favor and close this case.
SO ORDERED.
Notes
. The Court has subject matter jurisdiction over this Section 10(b) claim under 28 U.S.C. § 1331, and venue is proper.
. See GAMCO Investors, Inc. v. Vivendi, S.A. ("SJ Op.”),
. See JPTO at 13.
. See Plaintiffs’ Trial Memorandum of Law ("PL Mem.”) at 1.
. See JPTO at 3. More specifically, the parties stipulate that, during the Relevant Period, the market for Vivendi ADS’s was efficient under the factors set forth in Cammer v. Bloom,
. See JPTO at 13. But cf. id. at 13 n. 2 (stating that this stipulation is contingent on the prospective judgment in the Vivendi class action not being reversed, modified, or vacated on appeal).
. Familiarity with the prior proceedings in this case is assumed.
. See JPTO at 3.
. See id.; Pl. Mem. at 3. Somewhat confusingly, GBL changed its name in 2005 to GAMCO Investors, Inc., which, during the Relevant Period, was the name of a separate entity that is a plaintiff in this case. See 2/18/13 Trial Transcript ("Tr.”) (Direct Examination of Douglas Jamieson ("Jamieson Direct”)) at 116:6-12. The companies in question will be referred to by their Relevant Period names, except where otherwise noted.
. See JPTO at 3.
. See 2/18/13 Tr. (Jamieson Direct) at 117:5— 22.
. See id. at 118:10-119:12.
. See id. at 118:14-17.
. See id. at 120:10-17.
. JPTO at 3.
. See 2/18/13 Tr. (Jamieson Direct) at 122:6-8.
. Certain facts found in this section are drawn from the opinion In re Vivendi Universal, S.A. Sec. Litig.,
. See JPTO at 3.
. See id.
. The parties stipulated that Woodson was unavailable for trial within the meaning of FRCP 32(a)(4). See JPTO at 14 n. 3. As a result, his testimony was received through a videotaped deposition played in court during the first day of the trial. This presentation allowed the Court to evaluate Woodson’s demeanor. The parties subsequently submitted a transcript of Woodson’s deposition for the Court's review.
. See 2/18/13 Tr. (Direct Examination of Andrew Rittenberry ("Rittenberry Direct”)) at 30:3-31:1.
. See id. at 31:2-20.
. See id. at 33:3-5.
. See id. (Jamieson Direct) at 115:1-5.
. See id. at 115:14-115:3.
. See id. (Direct Examination of Bruce Alpert ("Alpert Direct")) at 131:22-132:7.
. See id. at 132:17-19; 133:25-134:10.
. See 8/3/06 Deposition of Anthony Harts-well Woodson III ("Woodson Dep.”) at 6:17-7:16.
. See id. at 7:17-24.
. Id. at 17:19-20:16; 25:12-23.
. See 2/19/13 Tr. (Direct Examination of Mario Gabelli ("Gabelli Direct”)) at 159:1-10.
. See id. at 159:16-19; Woodson Dep. at 20:4-16.
. See, e.g., 2/19/13 Tr. (Gabelli Direct) at 193:16-24 ("Q. [Referring to an article written by Mario Gabelli] Does that [passage] suggest that the [ ] public market price might not be an accurate reflection of intrinsic value, depending upon investor psychology? A. On a given day, the market knows everything that exists to the degree that that price in the public market reflects that, that would reflect all of the elements. For example, when President Eisenhower got assassinated — not assassinated, had a heart attack, the market dropped sharply. And it reflected that dynamic.”); id. at 227:18-228:6 (Redirect Examination of Mario Gabelli ("Gabelli Redirect”)) (“Q. Do you actually remember what determinations preceded your decision to purchase Vivendi stock during the [R]elevant [P]eriod? A. The mosaic that I follow, as a
. See id. at 191:7-23 (discussing Defendant’s Exhibit ("DX”) Z at 00000033-35) (pin citations to exhibits refer to their Bates numbers) (article prepared for Cigar Afficionado Magazine, under Mario Gabelli’s name, affixed to December 31, 2001 Annual Report of The Gabelli Asset Fund) ("The Court: Do you know if this is the text of an article you wrote for Cigar Afficionado? The Witness: You know, I can’t remember, but my name is on it, and I have had help preparing and editing articles in the past. And this may be one of those. Q: By allowing your name to be put on it, did you adopt it as yours? A: I don't understand the question. The Court: Well, by letting it be published as an article by Mario J. Gabelli,' did you acknowledge it as yours? The Witness: I never wrote to anyone telling them it’s not something I can live with. I probably didn't read it after it was published anyway. The Court: That’s not the question. The Witness: I know. The Court: If it says 'by Mario Gabelli,’ do you understand and accept that it’s yours? The Witness: I have never refuted that it was mine.”).
. See 12/31/2000 DX D, at 00000017.
. 2/19/13 Tr. (Gabelli Direct) at 199:12-13.
. See id. at 199:14-200:2.
. Id. (Gabelli Redirect) at 226:10-15.
. Id. (Plaintiffs’ Summation) at 233:22-24.
. DX J (3/31/01 Gabelli Asset Management Inc. PowerPoint Presentation) at 134.0011.
. Id. at 134.0017.
. See Woodson Dep. at 145:5-7.
. See id. at 145:7-21. See also DX Z at 00000033 ("It is our, and every prudent investor’s job to try to determine the intrinsic value of an individual company or the market as a whole.... Whether stocks trade at, above, or below intrinsic value is a function of investor psychology. Mr. Market is the code name the traditional value investor uses to personify investor psychology.”).
. 2/18/13 Tr. (Rittenberry Direct) at 43:4 — 14. See Woodson Dep. at 149:14-22.
. See Woodson Dep. at 86:17-87:8.
. Id. at 86:24-87:21.
. See, e.g., DX N (5/12/01 Gabelli Asset Management, Inc. PowerPoint presentation, Sixteenth Annual Meeting held at the Pierre Hotel, New York City) at 0042-0044 (describing GBL’s "investment process” as ”identify[ing] [the] intrinsic value of each business”); id. at 0049 (a graph entitled "PMV vs. Mr. Market” showing that GBL's investment strategy is to buy shares when their public market value is below their PMV per share); DX AZ (7/26/06 Gabelli promotional materials sent to investors) at 0009 ("Our goal is to identify companies in the public market that are selling at differences to their intrinsic or private market values”); DX BE (12/27/12 print-out from GAMCO website) ("GAMCO Investors, Inc. is best known for its research-driven, value-oriented equity investing expertise ... investing in undervalued companies that have a high probability of achieving their intrinsic or private value over time.”); Woodson Dep. at 77:17-24 ("[E]very analyst [at GBL] typically does an in-depth analysis of the companies that they’re covering by constructing an Excel type based spreadsheet [i.e., PMV] which analyzes the different business segments of the firm in order to establish what we think its intrinsic value is[.]”); 2/18/13 Tr. (Jamieson Direct) at 123:6-12 (”Q. And undervalued in this context means that the public stock price of a company was trading below its intrinsic value, correct? A. Yes. Q. And that intrinsic value was represented by GAMCO's calculation of that company’s [PMV], right? A. Yes.”).
. See 2/18/13 Tr. (Rittenberry Direct) at 47:15-17.
. See DX AU (01/11/01 print-out of Rittenberry spreadsheet calculating Vivendi’s PMV).
. See DX X (2001 print-out of Rittenberry spreadsheet calculating Vivendi’s PMV, containing handwritten notes by Gabelli); 2/19/13 Tr. (Gabelli Redirect) at 229:19-230:2; 2/18/13 Tr. (Rittenberry Direct) at 61:2-21.
. See 2/18/13 Tr. (Rittenberry Direct) at 63:2-20; DX K (4/5/01 e-mail from Rittenberry to Marc Gabelli and Vincent Roche).
. See Woodson Dep. at 238:17-239:20.
. See DX G, N, T.
. See 2/18/13 Tr. (Rittenberry Direct) at 72:7-20; 83:23-24; 84:10-17.
. See id. (Rittenberry Direct) at 85:10-86:10; id. (Cross-Examination of Rittenberry) at 90:17-21 (“The Court: If the price was inflated and you stripped that inflation out, the market value would be even lower and the discount would be bigger, between the private market and the market price, right? The Witness: Yes.”). See also DX AB (2/1/01 email from Rittenberry to Ken Egusa, analyst at Gabelli & Co. tasked with analyzing certain Japanese companies) (indicating that Rittenberry was aware that Vivendi had liquidity issues).
. See 2/18/13 Tr. (Rittenberry Direct) at 86:11-87:1 (testifying that Mario Gabelli is a long-term investor, and that, during the Relevant Period, he believed that the liquidity problems at Vivendi were a short-term problem).
. 6/25/07 Deposition of Mario Gabelli at 190:22-194:23.
. 2/19/13 Tr. (Gabelli Redirect) at 223:6.
. Id. (Jamieson Direct) at 119:22-25. Accord id. at 128:17-129:23 (testifying that GAMCO and the Mutual Fund Plaintiffs used PMV, supplemented by earnings per share and free and clear cash flow, to make investment decisions); id. (Alpert Direct) at 134:23-135:20 (verifying that the Mutual Fund Plaintiffs and GAMCO utilized the spread between PMV and market price to make investment decisions).
. See JPTO at 7-11.
. See 2/18/13 Tr. (Plaintiffs' Opening Argument) at 10:6-10.
. See DX V (8/20/02 GBL Morning Meeting Notes) at 0003.
. In re Vivendi Universal, S.A. Sec. Litig.,
. 2/19/13 Tr. (Gabelli Redirect) at 222:23-25.
. Ashland Inc. v. Morgan Stanley & Co., Inc.,
. See ATSI Commc’ns, Inc. v. Shaar Fund, Ltd.,
. Erica P. John Fund, Inc.,
.
. Basic,
. In re Salomon Analyst Metromedia Litig.,
. See Erica P. John Fund, Inc.,
. Dura Pharm., Inc. v. Broudo,
. In re Am. Int’l Grp., Inc. Sec. Litig.,
. Basic,
. Erica P. John Fund, Inc.,
. Until recently, plaintiffs in this Circuit also had to show materiality in order to proceed with a class action on a fraud on the market theory. See In re Salomon Analyst Metromedia Litig.,
. Basic,
. See id.
. See Daniel R. Fischel, Efficient Capital Markets, the Crash, and the Fraud on the Market Theory, 74 Cornell L. Rev. 907, 918-19 (1988) ("In the first situation where the market price is not artificially inflated because the truth becomes known from other sources, it is inaccurate to suggest that the presumption of reliance is rebutted. In fact, the example has nothing to do with reliance. Investors do not rely any less on the market price because that price has not been artificially inflated. It would be more accurate to characterize this situation as one where no fraud on the market occurred.”).
. Cf. In re Initial Public Offerings (“IPO”) Sec. Litig.,
. See In re Vivendi Universal, S.A. Sec. Litig.,
. In re Am. Int'l Grp., Inc. Sec. Litig.,
. In re Vivendi Universal, S.A. Sec. Litig.,
. See, e.g., In re Lehman Bros. Sec. & ERISA Litig., No. 08 Civ. 5523,
. See In re Vivendi Universal, S.A. Sec. Litig.,
. Basic,
. Id.
. In re Am. Int’l Grp., Inc. Sec. Litig.,
. In re LTV Sec. Litig.,
. duPont v. Brady,
. Basic,
. Amgen Inc. et al., 568 U.S. -,
. Erica P. lohn Fund, Inc.,
. ATSI Commc'ns, Inc.,
. Id.
. In re Am. Int’l Grp., Inc. Sec. Litig.,
. See, e.g., In re WorldCom, Inc. Sec. Litig.,
.
. See id. at 208.
. Black v. Finantra Capital, Inc.,
. Black,
. See Basic,
. 2/19/13 Tr. (Vivendi’s Closing Argument) at 261:7.
. Id. (Plaintiffs’ Closing Argument) at 244:6-7 ("Mr. Cappucci: I understand that. And what I’m saying is that they relied on price. They relied on price.”).
. 2/11/13 Plaintiffs' Trial Memorandum of Law (“Pl. Mem.”) at 6.
. See id. at 7 (citing Darquea v. Jarden Corp., No. 06 Civ. 722,
.
. Pl. Mem. at 8 (quoting In re IPO Sec. Litig.,
. Basic,
. See 2/19/13 Tr. (Plaintiffs' Closing Argument) at 235:16-236:7.
. See id. at 235:16-237:10.
. Basic,
. Cf. Dura Pharm., Inc.,
